MarketCapExport financials
Tabula Rasa HealthCare (TRHC)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Tabula Rasa HealthCare Income Statement 2022-2011 | TRHC
Brief overview of profit and loss at Tabula Rasa HealthCare
This overview is based on financial performance over the past five years. The revenue attributed to Tabula Rasa HealthCare moved from 133 million dollars to 300 million dollars between the two endpoints. Overall revenue changed by +124.4%, equal to an annualized rate of about 17.5%. Top-line growth remained consistently strong over the period.
Gross profit was $40.9 million at the start and $66.9 million at the end of the period (+63.6%). Cost of revenue developed less favorably than sales and pressured gross profitability. Comparing the endpoints gives gross margins of 30.6% and 22.3%. The business retained less gross profit from each unit of revenue.
EBITDA was $13.7 million at the beginning and −$45.6 million at the end of the period (−434.2%). EBITDA underperformed the top-line trend. The EBITDA share of revenue changed from 10.2% to −15.2%. Cost pressure reduced operating profitability.
The net financial result changed from 12.8 million dollars to −148 million dollars. The business lost profitability by the end of the period.
Market value was $541 million at the start and $135 million at the end. The market has not yet confirmed the improvement in fundamentals.
Financial takeaway
The current trajectory does not yet confirm a sustainable recovery. The financial profile benefits from a larger revenue base. The weaker side of the profile includes a narrow EBITDA buffer, pressure on operating profitability and a weaker final result. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Tabula Rasa HealthCare
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
135 M | 133 M | 885 M | 1.16 B | 1.05 B | 541 M | 106 M | - | - | - | - | - |
Shares |
24.3 M | 23.3 M | 21.8 M | 20.6 M | 19.1 M | 16.7 M | 7.49 M | 4.32 M | 4.05 M | - | - | - |
Historical Prices |
5.55 | 5.7 | 40.5 | 56.2 | 55.1 | 32.3 | 14.2 | - | - | - | - | - |
Net Income |
-148 M | -79.1 M | -81 M | -32.4 M | -47.3 M | 12.8 M | -5.52 M | -2.86 M | -1.11 M | -3.87 M | - | - |
Revenue |
300 M | 260 M | 221 M | 285 M | 204 M | 133 M | 94.8 M | 70 M | 48.4 M | 25.1 M | - | - |
Cost of Revenue |
233 M | 193 M | 161 M | 181 M | 138 M | 93.7 M | 65.2 M | 49.1 M | - | - | - | - |
Gross Profit |
- | - | - | 103 M | 66.6 M | 40.9 M | 9.37 M | 5.84 M | 10.6 M | 4.22 M | - | - |
Operating Income |
-69 M | -42.7 M | -41.2 M | -32.6 M | -49.7 M | 4.14 M | 5.28 M | 6.16 M | 107 K | - | - | - |
Interest Expense |
1.06 M | 9.11 M | 20.7 M | 16 M | 906 K | 688 K | 4.49 M | 5.92 M | 1.35 M | - | - | - |
EBITDA |
-45.6 M | -22.3 M | -24.5 M | 1.63 M | -32.9 M | 13.7 M | 10.4 M | 10.1 M | 1.92 M | -1.37 M | - | - |
Operating Expenses |
136 M | 109 M | 102 M | 136 M | 116 M | 35.7 M | 24.3 M | 14.7 M | 10.5 M | 6.71 M | - | - |
General and Administrative Expenses |
75 M | 63.1 M | 55.1 M | 50.9 M | 28.2 M | 21.2 M | 11.9 M | 7.12 M | 3.97 M | 2.48 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Tabula Rasa HealthCare
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
25.4 M | 25.2 M | 27.1 M | 24.4 M | 24 M | 23.9 M | 25.7 M | 23.4 M | 23.3 M | 23 M | 24 M | 21.8 M | 21.6 M | 21.4 M | 22.3 M | 20.7 M | 20.5 M | 20.4 M | 20.6 M | 19.2 M | 19 M | 18.8 M | 19.3 M | 16.7 M | 16.5 M | 16.2 M | 16.6 M | 4.92 M | 4.86 M | 4.67 M | 4.58 M | 4.38 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-9.85 M | -15.9 M | - | -40.1 M | -49.6 M | -28.2 M | - | -17.1 M | -21.1 M | -19.5 M | - | -21.6 M | -14.3 M | -14.4 M | -6.82 M | -8.1 M | -6.53 M | -11 M | -10.6 M | 10.4 M | -29 M | -18.1 M | 10.9 M | 7.7 M | -1.46 M | -2.88 M | -6.03 M | -142 K | -286 K | 209 K | 1.5 M | -3.26 M | -1.24 M | -696 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
90 M | 88.3 M | - | 77.1 M | 72.6 M | 67.1 M | - | 86.6 M | 82.3 M | 76.7 M | - | 70.5 M | 76.8 M | 72.8 M | 73.2 M | 74.3 M | 76.3 M | 61 M | 57.3 M | 54.4 M | 48.6 M | 43.9 M | 43.9 M | 33.3 M | 29.7 M | 27.7 M | 27.3 M | 24.2 M | 22.4 M | 20.2 M | 19.8 M | 18 M | 16.8 M | 15.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
67.5 M | 67.5 M | - | 60.2 M | 56.6 M | 52.7 M | - | 61.2 M | 57.3 M | 54 M | - | 49.2 M | 51.7 M | 48.1 M | - | 46.4 M | 45.2 M | 41.7 M | - | 35.1 M | 32.4 M | 31.7 M | - | 23.5 M | 21 M | 19.7 M | - | 17.2 M | 16.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.8 M | 8.69 M | 8.03 M | 9.37 M | 6.99 M | 6.3 M | 6.22 M | 5.84 M | 5.68 M | 4.82 M | 4.57 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-9.03 M | -6.16 M | - | -23.6 M | -10.1 M | -17.9 M | - | -14.7 M | -18.8 M | -16.7 M | - | -18.7 M | -10.2 M | -13.2 M | -7.8 M | -7.76 M | -4.76 M | -12.3 M | -9.34 M | 9.81 M | -34.8 M | -15.4 M | 8.78 M | -236 K | -1.22 M | -2.71 M | -248 K | 1.71 M | 1.48 M | 1.61 M | 2.01 M | 1.53 M | 1.77 M | 853 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
566 K | 452 K | - | 479 K | -2.44 M | -2.27 M | - | 2.23 M | 2.18 M | 2.55 M | - | 4.72 M | 4.67 M | 4.61 M | - | 4.44 M | 4.31 M | 2.69 M | - | 232 K | 120 K | 63 K | - | 174 K | 77 K | 76 K | - | 1.24 M | 1.5 M | 1.5 M | - | 1.47 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-2.93 M | 44 K | - | -17.9 M | -4.6 M | -12.2 M | - | -2.65 M | -7.15 M | -5.12 M | - | -6.5 M | 61 K | -3.28 M | -7.8 M | 1.38 M | 4.32 M | -6.03 M | -9.34 M | 13.9 M | -30.9 M | -11.3 M | 8.78 M | 1.93 M | 577 K | -945 K | -248 K | 2.98 M | 2.61 M | 2.62 M | 2.01 M | 2.52 M | 1.77 M | 853 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
31.6 M | 26.9 M | - | 40.5 M | 26.1 M | 32.3 M | - | 40.2 M | 43.8 M | 39.4 M | - | 40 M | 35.3 M | 37.9 M | - | 35.6 M | 35.9 M | 31.6 M | - | 9.55 M | 51 M | 27.7 M | - | 10 M | 9.91 M | 10.7 M | - | 5.28 M | 4.82 M | 4.61 M | - | 4.14 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
17.6 M | 16.6 M | - | 27.9 M | 15.2 M | 15.9 M | - | 16.9 M | 19.9 M | 17.5 M | - | 15.6 M | 16.3 M | 17 M | - | 12.2 M | 12.9 M | 13.7 M | - | 7.82 M | 6.53 M | 5.88 M | - | 4.1 M | 5.49 M | 6.51 M | - | 2.05 M | 1.82 M | 1.89 M | - | 2.08 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Tabula Rasa HealthCare (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Health information services industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B |  USA |
 |
OptimizeRx Corporation
OPRX
|
$ 9.34 | -1.37 % | $ 173 M | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B | USA |
 |
10x Genomics
TXG
|
$ 62.88 | -3.34 % | $ 7.84 B | USA |
 |
Veeva Systems
VEEV
|
$ 306.1 | -0.1 % | $ 50.1 B | USA |
 |
SCWorx Corp.
WORX
|
$ 1.31 | -5.76 % | $ 9.53 M | USA |
 |
Zhongchao
ZCMD
|
$ 0.94 | -5.99 % | $ 3.21 M |  China |
 |
HealthStream
HSTM
|
$ 28.69 | -0.14 % | $ 861 M | USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
So-Young International
SY
|
$ 2.0 | 0.5 % | $ 156 M | China |
 |
American Well Corporation
AMWL
|
$ 12.0 | -3.73 % | $ 193 M | USA |
 |
Evolent Health
EVH
|
$ 4.79 | 1.7 % | $ 547 M | USA |
 |
GoodRx Holdings
GDRX
|
$ 3.54 | -3.01 % | $ 1.26 B | USA |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
Health Catalyst
HCAT
|
$ 1.46 | -3.31 % | $ 102 M | USA |
 |
HealthEquity
HQY
|
$ 103.68 | 1.53 % | $ 8.93 B | USA |
 |
Omnicell
OMCL
|
$ 35.87 | -3.96 % | $ 1.65 B | USA |
 |
Progyny
PGNY
|
$ 36.44 | 1.35 % | $ 3.11 B | USA |
 |
Schrödinger
SDGR
|
$ 32.42 | -2.89 % | $ 2.38 B | USA |
 |
Teladoc Health
TDOC
|
$ 8.96 | -0.28 % | $ 1.58 B | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Phreesia
PHR
|
$ 13.15 | 1.94 % | $ 786 M | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |